

EASL HCC Summit 2019

Shaping the future in liver cancer therapy: Current clinical standards, emerging opportunities and new molecular principles

Lisbon, Portugal

Thursday 14 to Saturday 16 February 2019

Organisers:

Sandrine Faivre, France

Tom Lüdde, Germany

Maria Reig, Spain

Thursday 14 February

Welcome and introduction

13:00 – 13:15 | Sandrine FAIVRE, *France*
Tom LÜDDE, *Germany*
Maria REIG, *Spain*

Moving the field toward translational medicine – is there a link between biological profiling and clinical decision-making?

Chairs: Tom LÜDDE, *Germany*; Helen Louise REEVES, *United Kingdom*

13:15 - 13:45 | **The genomic landscape of HCC: Implications for diagnosis and therapy**
Jessica ZUCMAN-ROSSI, *France*

13:45 - 14:15 | **Cholangiocarcinoma and combined HCC/CCA: Morphological and genetic classification for targeted therapies**
Peter SCHIRMACHER, *Germany*

14:15 - 14:45 | **Impact of the adenoma molecular profile in the clinical decision-making**
Valérie PARADIS, *France*

ePoster session 1 and coffee break

14:45 – 15:15

Biological principles and clinical specificities in NAFLD and NASH-derived liver cancer - Part 1

Chairs: Salvatore PETTA, *Italy*; Massimo PINZANI, *United Kingdom*

15:15 - 15:45 | **Epidemiology and non-invasive tools for HCC surveillance in populations at risk**
Salvatore PETTA, *Italy*

15:45 - 16:15 | **Platelets and immune mechanisms in NASH-derived HCC development**
Mathias HEIKENWÄLDER, *Germany*

16:15 - 16:30 | **Abstract Presentation: Genome wide RNA expression analysis identifies CD44 positive macrophages as promoters of hepatocyte proliferation and the development of NAFLD-HCC**
Misti MCCAIN, *United Kingdom*

16:30 - 16:45 | **Abstract presentation: NASH-related liver carcinogenesis is critically affected by hypoxia-inducible factor 2-alpha**
Beatrice FOGLIA, *Italy*

16:45 - 17:15 | **Novel approaches to precision medicine in Liver Cancer**
Xin WEI WANG, *United States*

ePoster session 2 and coffee break

17:15 - 17:45

Biological principles and clinical specificities in NAFLD and NASH-derived liver cancer - Part 2

Chairs: Salvatore PETTA, *Italy*; Massimo PINZANI, *United Kingdom*, Tom LÜDDE, *Germany*

Clinical considerations in medical and surgical treatments of NASH-derived HCC:

- 17:45 - 18:00 **The hepatologist's perspective**
Helen Louise REEVES, *United Kingdom*
- 18:00 - 18:15 **The West surgeon's perspective**
Vincenzo MAZZAFERRO, *Italy*
- 18:15 - 18:30 **The East surgeon's perspective**
Norihiro KOKUDO, *Japan*

State-of-the-art lecture

- 18:30 - 19:15 **New Developments in targeted therapy of Cancer**
Yinon BEN-NERIAH, *Israel*

Welcome reception and ePoster session 3

19:15 – 19:45

Friday 15 February

New diagnostic and translational tools in cancer

Chairs: Robert SCHWABE, *United States*; Lars ZENDER, *Germany*

- 08:00 - 08:20 **In-vivo functional screening approaches for discovering novel oncogenic pathways in liver cancer**
Lars ZENDER, *Germany*
- 08:20 - 08:40 **Organoid Models of Human Liver Cancers**
Markus HEIM, *Switzerland*
- 08:40 - 08:55 **Abstract presentation: Mixed HCC-ICC liver cancer derived from hepatic progenitor cells- a lineage tracing investigation in a mouse liver inflammation model**
Nofar ROSENBERG, *Israel*
- 08:55 - 09:10 **Abstract presentation: Non-autonomous induction of endothelial Inducible T-cell co-stimulator ligand may underpin immune-mediated senescence surveillance**
Kelvin CHUAN HSIN, *United Kingdom*
- 09:10 - 09:30 **Transgenic mouse models for studying cell type specific functions in liver cancer**
Robert SCHWABE, *United States*
- 09:30 - 09:50 **An integrated screening approach in different mouse HCC models**
Tom LÜDDE, *Germany*

Poster Blast

09:50 - 10:20

Chair: Tom LÜDDE, *Germany*; Jessica ZUCMAN-ROSSI, *France*
Poster Blast

ePoster session 4 and Coffee break

10:20 – 11:00

Clinical challenges and controversies in liver cancer management - Part 1 - What is the best option for my patient with a single 2.1 cm HCC (BCLC A)? Tumour board #1

Chair: Marcus-Alexander WÖRNS, *Germany*

11:00 - 11:15

Clinical case presentation

Maria VARELA, *Spain*

11:15 - 11:20

Brief presentation

Irene BARGELLINI, *Italy*

11:20 - 11:25

Brief presentation

Christian TOSO, *Switzerland*

11:25 - 11:30

Brief presentation

Maria VARELA, *Spain*

11:30 - 11:45

Discussion

Chair and all the speakers

Clinical challenges and controversies in liver cancer management - Part 1 - DAA therapy and development/recurrence of HCC: Analysis of current data. Tumour board #2

Chairs: Massimo COLOMBO, *Italy*; Maria REIG, *Spain*

11:45 - 11:55

Presentation of clinical current data

Giuseppe CABIBBO, *Italy*

11:55 - 12:03

Clinical case presentation

Martina GAMBATO, *Italy*

12:03 - 12:08

Epigenetic point of view

Thomas BAUMERT, *France*

12:08 - 12:13

Immunology point of view

Eli PIKARSKY, *Israel*

12:13 - 12:18

Virology point of view

Pablo GASTAMINZA, *Spain*

12:18 - 12:30

Discussion

Chairs and all the speakers

Lunch

12:30 – 13:30

The rising challenge of cholangiocarcinoma

Chairs: Jesus M. BAÑALES, *Spain*; Jessica ZUCMAN-ROSSI, *France*

13:30 - 13:55

Epidemiology, risk factors and management of CCA

Shahid KHAN, *United Kingdom*

13:55 - 14:20

Novel diagnostic and prognostic biomarkers in PSC and CCA

Jesus M. BAÑALES, *Spain*

14:20 - 14:35

European Cholangiocarcinoma (EU-CCA) Registry: An initiative to broaden awareness on the second most common primary liver cancer

Alvaro SANTOS-LASO, *Spain*

14:35 - 15:00

Pharmacogenetics as a novel therapeutic approach for cholangiocarcinoma

15:00 - 15:25	Jesper ANDERSEN, <i>Denmark</i> Surgery and transplantation for CCA: Options and limits Gonzalo SAPISOCHIN, <i>Canada</i>
15:25 - 15:50	New horizons for precision medicine in biliary tract cancer Juan VALLE, <i>United Kingdom</i>

ePoster session 5 and coffee break

15:50 – 16:30

Clinical challenges and controversies in liver cancer management - Part 2 - The heterogeneity of multinodular HCC patients: Can we define a personalized approach? Tumour board #3

	Chair: Fabio PISCAGLIA, <i>Italy</i>
16:30 - 16:45	Clinical case presentation Sherrie BHOORI, <i>Italy</i>
16:45 - 17:15	Discussion Moderator: Fabio PISCAGLIA, <i>Italy</i> Clinical point of view Alejandro FORNER, <i>Spain</i> Surgical point of view Norihiro KOKUDO, <i>Japan</i> Molecular point of view Jean-Charles NAULT, <i>France</i> Radiological point of view Jens RICKE, <i>Germany</i>

What is the future of clinical trial design in HCC?

	Chairs: Lorenza RIMASSA, <i>Italy</i> ; Peter GALLE, <i>Germany</i>
17:15 - 17:30	What are the needs of the academia in the HCC field? Peter GALLE, <i>Germany</i>
17:30 - 17:45	Response criteria to evaluate drug activity and their surrogate value for survival Jordi BRUIX, <i>Spain</i>

ePoster session 6 and coffee break

17:45 – 18:15

Roundtable with industry in the field and EMA/FDA

	Chairs: Jordi BRUIX, <i>Spain</i> ; Peter GALLE, <i>Germany</i>
18:15 – 19:20	Speaker view Naomi HORIBA - FDA Paolo FOGGI - EMA Emmanuelle DOCHY - Bayer Fawzi BENZAGHOU - Ipsen Dimitris VOLIOTIS - Eisai Paolo ABADA - Lilly Jeff ANDERSON - BMS Liz CROYDON - Merck Herb HURWITZ - Roche

Saturday 16 February

Advanced HCC: a multidisciplinary approach

Chairs: Jordi BRUIX, *Spain* ; Sandrine FAIVRE, *France*

- 08:00 - 08:30 **Approved systemic 1st line treatments for HCC: Is there evidence for a personalized approach?**
Maria REIG, *Spain*
- 08:30 - 09:00 **Second line systemic treatment of HCC: Clinical trials and clinical reality**
Lorenza RIMASSA, *Italy*
- Top scorer and late breaker abstracts**
- 09:00 - 09:10 **Ramucirumab for patients with HCC and elevated alpha-fetoprotein following sorafenib treatment: exploratory analysis of REACH-2 trial results by albumin-bilirubin grade and child-pugh score**
Peter GALLE, *Germany*
- 09:10 - 09:20 **A multicenter international study of sorafenib treatment in patients with hepatocellular carcinoma and chronic kidney disease undergoing hemodialysis**
Alvaro DIAZ-GONZALEZ, *Spain*
- 09:20 - 09:30 **Exploiting senescence for the treatment of liver cancer**
Cun, WANG, *Netherlands*
- 09:30 - 09:50 **Adverse events management in TKI-treatment and immunotherapy**
Sandrine FAIVRE, *France*
- 09:50 - 10:10 **New concepts for combining interventional and systemic therapies in HCC**
Sherrie BHOORI, *Italy*
- 10:10 - 10:30 **Emerging biomarkers for systemic HCC therapies**
Andrew X. ZHU, *United States*

ePoster session 7 and coffee break

10:30 - 11:00

The immune system in HCC and implications for immunotherapy

Chairs: Eli PIKARSKY, *Israel*; Bruno SANGRO, *Spain*

- 11:00 - 11:20 **Innate immune responses in hepatocarcinogenesis**
Frank TACKE, *Germany*
- 11:20 - 11:40 **Novel targets in immunotherapy of HCC**
Eli PIKARSKY, *Israel*
- Top scorer and late breaker abstracts**
- 11:40 - 11:50 **Late breaker abstract: A computational model for optimizing immunotherapy strategies in HCC based on early treatment response dynamics**
Jakob Nikolas, KATHER, *Germany*
- 11:50 - 12:00 **Dual targeting of G9a and DNMT-methyltransferase-1 for the treatment of experimental cholangiocarcinoma**
Maite, FERNANDEZ-BARRENA, *Spain*
- 12:00 - 12:15 **Combined CXCR2 inhibition and Anti-PD1 therapy alters neutrophil and T cell infiltration and limits HCC progression**
Jack LESLIE, *United Kingdom*
- 12:15 - 12:45 **Immunotherapy in HCC: Current evidence and future perspectives**
Bruno SANGRO, *Spain*
- 12:45 - 13:00 **Closing remarks and farewell**

